TEE
RVNC

Tibra Equities Europe’s Revance Therapeutics, Inc. RVNC Stock Holding History

Tibra Equities Europe’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,200
Closed -$287K – 457
2019
Q1 		$287K Buy
+18,200
New +$316K 0.03% 340

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Tibra Equities Europe's RVNC Position: Q2 2019 in Review

Tibra Equities Europe sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2019, closing a stake of 18,200 shares — an estimated $287K sold.

Tibra Equities Europe first reported a position in RVNC in Q1 2019 and held it in 1 quarter. The position peaked at $287K in Q1 2019. 114 funds tracked by Wall St. Rank hold RVNC as of Q2 2019.

  • Tibra Equities Europe reported no remaining Revance Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 18,200 Revance Therapeutics, Inc. shares in Q2 2019, an estimated $287K.
  • Tibra Equities Europe first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Revance Therapeutics, Inc. position peaked at $287K in Q1 2019.
  • 114 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.